Tag Archives: NVS

Novartis Discontinues LIK066 in obesity; Novartis and Abbott Q2 ’18 Earnings Updates

Novartis and Abbott both held their respective earnings calls today and provided updates to their respective commercial and pipeline products. Of note, Novartis disclosed it has discontinued development of LIK066 (dual SGLT1/2 inhibitor) for the treatment of obesity. Abbott believes it will be able to reach 1 million global Libre users by YE ’18. Below are highlights from the respective Q2 ’18 earnings calls.

This content is for Read Less members only.
Register
Already a member? Log in here

Novartis Q4 ’17 Earnings Update

Novartis hosted its Q4 and full year 2017 earnings updates. Novartis briefly discussed its SGLT1/2i (LIK066), which is being developed for obesity. Of note, Novartis said it anticipates completing their Ph2b trial in H2 ’18 with Ph3 to potentially initiate as early as YE ’18 or early 2019. Below are highlights from the calls.

This content is for Read Less members only.
Register
Already a member? Log in here